Sign inJoin waitlistJoin the waitlist

Sarah Tasian

Chief, Hematologic Malignancies Program · Children's Hospital of Philadelphia

Credentials: · · · · ·

History

Hematologic Malignancies Program Division · Children's Hospital of Philadelphia
Present
Children's Hospital of Philadelphia
Present

Pediatric Hematology Oncology
University of California-San Francisco
2007–2010
Pediatrics
University of Washington School of Medicine
2004–2007
Baylor College of Medicine
2000–2004
University of Notre Dame, 1999.
1995–1999

Research

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
New England Journal of Medicine · 2014 · 1,124 citations
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Proceedings of the National Academy of Sciences of the United States of America · 2009 · 431 citations
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Blood · 2014 · 414 citations

Mignon Loh
24 papers
Stephen Hunger
21 papers
David Teachey
13 papers
Richard Aplenc
13 papers
Martin Carroll
12 papers
Elliot Stieglitz
11 papers
Gerald Wertheim
11 papers
Todd Cooper
11 papers
Cheryl Willman
9 papers
Soheil Meshinchi
9 papers · 5 as a fellow
Stephan Grupp
9 papers
EK
Edward Kolb
8 papers

Grants

Optimized Targeting of FLT3 and Menin in KMT2A-R ALL toOvercome Immunotherapeutic Resistance
National Cancer Institute · R01
PI · $706.9K · University of Colorado Denver
2026–2031
Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-Like Acute Lymphoblastic Leukemia
National Cancer Institute · R01
PI · $3.5M · Seattle Children's Hospital
2025–2029
Towards Rational Design of Combination Therapeutic Targets
National Cancer Institute · U01
PI · $2.6M · Children's Hosp of Philadelphia
2020–2025
Multispecific Targeting Incorporating Cytokine Receptor Pathways in High Risk Pediatric Acute Leukemias to Improve Durability of Adoptive Cell Therapy-Induced Remissions
National Cancer Institute · U01
PI · $4M · University of Colorado Denver
2018–2024

Clinical trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Study chair · Completed · Phase 2
Incyte Corporation
2016–2026
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2026–2027
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Site PI · Recruiting · Phase 1
Children's Oncology Group
2025–2028